TriOar is focusing on developing
its proprietary platform technologies for
next-generation antibody therapeutics.

Antibody-based Therapeutics with
novel platform technologies
DB (Discovery Biology)
Specifically Targeting Cancer Lesions
AS (Antibody Screening)
Antibody Screening System for novel Antibodies and Optimization
DC (Discovery Chemistry)
Novel linker-toxin system with improved blood stability and faster drug release.
Type Discovery Biology

Discovery of Novel Targets
Optimization of a novel platform
Development of novel multispecific antibody formats

Antibody Screening

Advancement of Antibody screening methods

Discovery Chemistry

Optimization of a Novel Linker Platform
Payload Research

Work Scope Recombinant DNA work Establishment of fully human
phage-displayed antibody library
Novel Linker Synthesis
Transient protein production Novel antibody screening Toxin Synthesis
Protein purification/analysis Antibody Affinity maturation Process Optimization
ADC Analysis Antibody Humanization LC/MS and NMR Analysis
Cell Culture Antigen Epitope mapping
In vitro evaluation